Colchicine for the Stability of Coronary Plaque in Acute Coronary Syndrome (COLOCT)
NCT04848857 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 128
Last updated 2023-12-19
Summary
Evidence from the COLCOT Trial has shown that anti-inflammatory effect of colchicine reduced the risk of cardiovascular events in patients with recent myocardial infarction. We hypothesized that this might be due to the improvement of the coronary plaque stability by colchicine. Optical coherence tomography (OCT) is the most precise method to detect plaque stability in clinical practice. Thus, the purpose of this study is to evaluate the efficacy and safety of colchicine on improving the stability of coronary plaque in patients with acute coronary syndrome.
Conditions
- Acute Coronary Syndrome
Interventions
- DRUG
-
Colchicine
colchicine is a potent anti-inflammatory drug which is currently recommended for the treatment of pericarditis and acute gout attacks, but also familial Mediterranean fever and Behçet disease. This drug acts on inflammation through inhibition of microtubule polymerization by binding free tubule dimers. Colchicine blunts monocyte and neutrophil invasion at the site of inflammation and reduces intracellular trafficking and thus the release of cytokine and production of reactive oxygen species and a variety of proteolytic enzymes.
- DRUG
-
the placebo is a drug with no chemical effects but with the same physical characteristics as the experiment drug colchine.
Sponsors & Collaborators
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-05-03
- Primary Completion
- 2023-08-20
- Completion
- 2023-10-05
Countries
- China
Study Locations
More Related Trials
-
Anti-platelet Effects of Colchicine in Healthy Volunteers
NCT02140372 ·Status: COMPLETED ·Phase: PHASE4
-
Residual Inflammatory Risk-Guided colcHicine in Elderly Trial
NCT06025071 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation
NCT01094457 ·Status: COMPLETED ·Phase: PHASE4
-
Platelet Reactivity And Clinical ThrombotIC Events Study
NCT03525145 ·Status: UNKNOWN
-
Effect of Inflammasome Inhibitor on hsCRP in Patients After PCI
NCT05130892 ·Status: COMPLETED ·Phase: PHASE4
-
Tongxinluo Improve High on Clopidogrel Platelet Reactivity Patients With Coronary Heart Disease
NCT01721590 ·Status: COMPLETED ·Phase: PHASE4
-
Clopidogrel Maintaining Dosage in Acute Coronary Syndrome After Drug Eluting Stent Implantation
NCT00404053 ·Status: COMPLETED ·Phase: PHASE4
-
Platelet Inhibition in the Acute Phase of STEMI
NCT01144819 ·Status: COMPLETED
-
Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention
NCT06095765 ·Status: RECRUITING ·Phase: PHASE3
-
Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel
NCT00405717 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Amlodipine on Anti-platelet Drug Effect in Patients With Coronary Artery Disease
NCT01203696 ·Status: COMPLETED ·Phase: PHASE4
-
Platelet Reactivity in Stent Thrombosis Patients
NCT01012544 ·Status: COMPLETED ·Phase: PHASE4
-
Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Evaluation
NCT01860105 ·Status: COMPLETED ·Phase: PHASE1
-
Clopidogrel Efficacy and Acute Coronary Syndromes
NCT00839267 ·Status: COMPLETED
-
Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
NCT06933056 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Platelet Reactivity After Cessation of Clopid in the Setting of Coronary Stent Implantation I: PRACTICE I
NCT00684359 ·Status: COMPLETED
-
Investigation of the Athero-Protective Effects of Clopidogrel
NCT01283282 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Edoxaban on Platelet Aggregation
NCT05122455 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Platelet Reactivity After Receiving Clopidogrel Among Moderate CKD Patients Undergoing PCI
NCT02556671 ·Status: UNKNOWN
-
A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome
NCT00830960 ·Status: COMPLETED ·Phase: PHASE3
-
Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism
NCT00915733 ·Status: COMPLETED ·Phase: PHASE4
-
Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI
NCT03078465 ·Status: WITHDRAWN ·Phase: PHASE3
-
The Correlation Between Genetic Polymorphism, Platelet Activity, Clopidogrel Responsiveness, and Serum Adipokine Concentration in Asian Acute Coronary Syndrome Patients
NCT01255267 ·Status: UNKNOWN
-
Patent Versus Generic Clopidogrel in Acute Coronary Syndrome
NCT02628587 ·Status: UNKNOWN ·Phase: PHASE4
-
Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan
NCT01069302 ·Status: COMPLETED ·Phase: PHASE4